Boldenone Cypionate Raw Powder is a steroidal raw material also described as Boldenone cyclopentanepropionate or Bold Cyp. AAS Raw Pharma supplies white crystalline Boldenone Cypionate raw powder with a stated purity of 99.3% for qualified laboratory research, analytical reference work, method development, and legally authorised professional applications.
The compound is identified by CAS 106505-90-2 and the molecular formula C27H38O3. Buyers should note that the molecular formula and molecular weight printed in the original supplied content were incorrect: the formula listed as C26H38O3 and the weight listed as 398.58 g/mol both appear on some supplier pages, but independent reference sources consistently report C27H38O3 and approximately 410.59 g/mol. Boldenone Cypionate Raw Powder
AAS Raw Pharma supports qualified sample, development, and bulk enquiries subject to product availability, customer verification, destination regulations, and a documented lawful end use.
Important notice: This listing is for a bulk chemical raw material. It is not a finished veterinary medicine, sterile injectable preparation, dietary supplement, or consumer product, and it is not intended for direct human or veterinary administration. Boldenone Cypionate Raw Powder is controlled or otherwise regulated in many jurisdictions. Buyers are responsible for confirming that purchase, possession, importation, handling, storage, processing, and intended use are lawful in their own jurisdiction.
Boldenone Cypionate Raw Powder is the cypionate ester of boldenone, which is also known chemically as the cyclopentanepropionate ester. The ester group distinguishes this substance from Boldenone Undecylenate, Boldenone Acetate, Boldenone Propionate, and unesterified boldenone base.
The compound is widely associated with veterinary pharmaceutical development, and suppliers often describe it as an ester of boldenone marketed for veterinary purposes. Analytical reference catalogues list it as an anabolic androgenic steroid reference standard intended for forensic and research applications only.
AAS Raw Pharma supplies the material as a bulk raw ingredient. Availability of the raw substance does not mean that AAS Raw Pharma, the buyer, or the destination country permits veterinary manufacturing, clinical use, compounding, or personal administration.
| Specification | Product details |
|---|---|
| Product name | Boldenone Cypionate Raw Powder |
| Chemical name | Boldenone cyclopentanepropionate |
| Alternative chemical description | 17-beta-hydroxyandrosta-1,4-dien-3-one cyclopentanepropionate |
| Common market name | Bold Cyp |
| CAS number | 106505-90-2 |
| Molecular formula | C27H38O3 |
| Molecular weight | Approximately 410.59 g/mol |
| Stated purity | 99.3%, subject to batch documentation |
| Appearance | White crystalline powder |
| Physical form | Crystalline solid |
| Listed grade | Pharmaceutical raw-material grade |
| Material category | Steroidal research and manufacturing raw material |
| Packaging | Sealed foil bag or approved bulk packaging |
| Documentation | Batch-specific documents available on request, where applicable |
| Intended users | Qualified laboratories, institutions, and authorised manufacturers |
| Direct administration | Not permitted; this is not a finished product |
The formula and molecular weight are supported by multiple independent reference sources. A certified reference material certificate from NMIA lists C27H38O3 and 410.6 g/mol for Boldenone Cypionate at CAS 106505-90-2. Cayman Chemical records the same formula with a formula weight of 410.6, and LGC’s TRC listing states 410.59.
Final product acceptance should be based on the batch label, agreed specification, available Certificate of Analysis, and the customer’s own quality procedures rather than on a general website description.
The original draft of this product listing contained two specification errors that should be corrected before publication:
| Field | Originally listed | Correct value |
|---|---|---|
| Molecular formula | C26H38O3 | C27H38O3 |
| Molecular weight | 398.58 g/mol | Approximately 410.59 g/mol |
| Alias | Boldenone cyclopentanepropionate | Correct, and should be listed as a chemical name rather than an alias |
The C26H38O3 and 398.58 values appear on some raw-material supplier pages, but they do not match the CAS-assigned identity for Boldenone Cypionate. Publishing contradictory identity data on a single page damages buyer confidence and creates avoidable receiving and documentation problems.
Where a supplier catalogue shows conflicting values, buyers should verify identity against an authoritative source before ordering.
Boldenone Cypionate is identified by:
LGC’s reference listing records the accurate mass as 410.2821 and gives the IUPAC name as the 3-cyclopentylpropanoate ester of the androsta-1,4-dien-17-yl structure. Chemical databases list Bold Cyp, BC 250, and Boldenone cyclopentanepropionate among the recognised synonyms.
These identifiers should appear consistently in quotations, purchase orders, labels, certificates, and receiving records. Using both the full chemical name and CAS number reduces the risk of confusion with other boldenone esters.
The material may appear under several names:
Cayman Chemical records the synonym 17-beta-hydroxy-androsta-1,4-dien-3-one cyclopentanepropionate, and VWR lists the same systematic description alongside the CAS number.
For procurement accuracy, the recommended description is Boldenone Cypionate Raw Powder, CAS 106505-90-2.
AAS Raw Pharma describes the product as a white crystalline powder. Several current raw-material catalogues describe a similar white to pale yellow crystalline powder. Cayman Chemical describes its reference material as a crystalline solid, while the NMIA certified reference standard is described as an off-white solid.
Colour can vary slightly between batches and does not confirm identity, assay, or purity. Visual inspection should be one part of an incoming-material procedure that includes documentation verification and appropriate analytical testing.
A white crystalline appearance also does not establish that the material is sterile, endotoxin-controlled, suitable for injection, or released for any regulated use.
The stated purity for this product is 99.3%, subject to confirmation in the documentation for the supplied batch. A purity figure should always be read together with the method used, the batch tested, the acceptance criteria, and the resulting report.
For context, reference-material suppliers publish different specifications for different purposes. Cayman Chemical lists a purity of at least 95% for its analytical reference standard, AChemBlock listed 97%, and the NMIA certified reference material carries a certified mass-fraction value of 97.3% with an uncertainty statement.
Those figures describe entirely different products and testing programmes. They cannot be used to support or contradict the AAS Raw Pharma batch, which must be documented on its own COA.
A Certificate of Analysis, or COA, is a batch-specific document summarising the tests performed and the results obtained for a defined lot. Depending on the AAS Raw Pharma specification, a COA may include:
Published supplier pages frequently promise a COA, HPLC purity report, product specification sheet, and batch testing documentation. Those documents are only meaningful when they correspond to the specific lot being supplied.
Customers should confirm that the lot number on the COA matches the lot number on the packaging, and should retain the documents with their incoming-material and release records.
Quality evaluation of a steroidal raw material can extend well beyond a single purity figure. Depending on the agreed specification and lawful intended application, assessment may cover:
AAS Raw Pharma should only claim tests that were actually performed and documented for the supplied batch. Avoid describing the product as HPLC tested, GC-MS verified, NMR confirmed, heavy-metal tested, residual-solvent tested, sterile, endotoxin-free, or pharmacopoeia compliant unless those results appear in the batch records.
Customers operating under formal quality systems should apply their own sampling, quarantine, testing, review, and release procedures.
The supplied draft describes this material as pharmaceutical grade. That description should be supported by a documented specification. It does not by itself establish that the powder is:
Some raw-material catalogues attach pharmacopeia and quality-standard labels such as USP/BP/ISO 9001 to boldenone listings without publishing the supporting documentation. Those claims should not be copied across to the AAS Raw Pharma listing unless AAS Raw Pharma holds current, verifiable evidence.
Precise wording is safer and more credible than a broad quality claim. If the product is manufactured against an internal or enterprise specification, describe it that way.
The supplied draft describes Boldenone Cypionate as a “very powerful version” of Boldenone Undecylenate. That framing is inaccurate and should be replaced with a straightforward chemical comparison.
| Feature | Boldenone Cypionate | Boldenone Undecylenate |
|---|---|---|
| Ester type | Cypionate (cyclopentanepropionate) | Undecylenate (10-undecenoate) |
| CAS number | 106505-90-2 | 13103-34-9 |
| Molecular formula | C27H38O3 | C30H44O3 |
| Molecular weight | Approximately 410.59 g/mol | Approximately 452.67 g/mol |
| Common association | Bold Cyp | Equipoise |
| Same raw material | No | No |
| Interchangeable | No | No |
These are two distinct esterified compounds. Neither is a “stronger version” of the other in a chemical sense; they differ in ester structure, molecular identity, and physical characteristics. A buyer should specify which ester is required before ordering.
Boldenone Cypionate and boldenone base are also different substances.
| Feature | Boldenone Cypionate | Boldenone base |
|---|---|---|
| Chemical form | Cyclopentanepropionate ester | Unesterified parent compound |
| CAS number | 106505-90-2 | 846-48-0 |
| Molecular formula | C27H38O3 | C19H26O2 |
| Molecular weight | Approximately 410.59 g/mol | Approximately 286.41 g/mol |
The FDA maintains a separate validated substance record for boldenone with CAS 846-48-0. Supplying the wrong boldenone form against an order is a real commercial risk when the product is described only as “boldenone.”
Subject to applicable law and customer qualification, Boldenone Cypionate raw material may be relevant to:
Reference suppliers consistently describe Boldenone Cypionate Raw Powder as intended for research and forensic applications rather than therapeutic use. That positioning is appropriate for a bulk raw material listing and should be reflected on this page as well.
Availability does not authorise any particular application. Each buyer must confirm that its organisation, personnel, facilities, licences, and intended activity comply with the applicable regulatory framework. Boldenone Cypionate Raw Powder
Boldenone Cypionate Raw Powder is associated with veterinary pharmaceutical development, and published material describes boldenone esters as veterinary anabolic agents. The University of Hertfordshire’s veterinary substance database describes Boldenone Undecylenate as an anabolic veterinary drug supplied as an oil suspension and identifies it as a controlled substance in the United Kingdom.
That information concerns finished veterinary medicinal products. It does not mean that bulk raw powder may be administered to an animal, mixed into feed, or used to prepare an unlicensed veterinary product. Boldenone Cypionate Raw Powder
Treatment decisions for any animal must be made by a licensed veterinarian using an appropriately authorised finished product. AAS Raw Pharma supplies raw chemical material, not veterinary treatment, and should not publish veterinary dosing or treatment-framework statements as part of the product listing. Boldenone Cypionate Raw Powder
Several passages in the supplied draft describe treatment frameworks and biological effects that are inappropriate for a raw-material product page. These should be removed or replaced with compliant wording:
| Remove or rewrite | Reason |
|---|---|
| “Adjunctive therapy to other specific and supportive therapy for diseases, surgical cases and traumatic injuries” | Medical treatment framework for a bulk raw ingredient |
| “The individual dosage should be determined by the veterinarian” | Dosage framework; inappropriate for raw material |
| “Will increase nitrogen retention, protein synthesis, appetite and stimulate erythropoietin release” | Therapeutic and physiological claims that are not established for this product |
| Descriptions of weight, strength, fat loss, red blood cell, endurance, or lean-mass effects | Personal-use and performance claims |
| “Very powerful version of Boldenone Undecylenate” | Chemically inaccurate comparison |
| “Treatment of debilitated horses” passages | Veterinary treatment claims for raw material |
| “Well disguised packing,” “100% custom rate,” “quality guarantee 100%” | Unsupportable shipping and quality assurances |
Removing these passages protects the page from unsubstantiated-claim risk and keeps the listing focused on what it actually is: a documented raw chemical material.
A crystalline raw material is fundamentally different from a sterile finished medicine. Manufacturing a regulated veterinary injectable requires controls that may include approved formulation development, qualified starting materials, validated facilities, sterility assurance, endotoxin control, particulate testing, container-closure qualification, stability studies, finished-product release testing, and regulatory authorisation.
A stated purity of 99.3% does not demonstrate sterility, freedom from endotoxins, injectable suitability, clinical safety, or regulatory approval. AAS Raw Pharma does not provide compounding, conversion, filtration, injection, or administration instructions.
Reference suppliers do not all specify the same storage condition. Cayman Chemical and LGC list -20 degrees C for their reference materials, while AChemBlock listed 0-8 degrees C for its discontinued reference compound. A certified reference material certificate from NMIA recommends storage at or below 4 degrees C in a closed container in a dry, dark area.
Those conditions apply to specific reference-material formats, not automatically to the AAS Raw Pharma raw powder. The correct storage condition must come from the product’s own label, specification, or stability data.
General storage practice:
Do not publish a specific storage temperature or shelf life for this product without supporting documentation.
Boldenone Cypionate Raw Powder should be treated as a hazardous substance in a professional setting. Cayman Chemical’s Safety Data Sheet assigns the signal word Danger and carries hazard statements indicating that the substance is suspected of causing cancer and may damage fertility or the unborn child.
Those hazard classifications apply to the reference material that Cayman assessed, but they underline why the raw powder should be handled only by trained personnel under a documented risk assessment. Appropriate controls may include restricted access, protective equipment, dust prevention, controlled sampling, dedicated or properly cleaned equipment, cross-contamination controls, spill procedures, and documented waste disposal.
The powder must not be tasted, swallowed, inhaled, injected, or applied to the body. It must be kept away from children and unauthorised persons. Personnel should review the applicable Safety Data Sheet before opening or handling the material.
Packaging should protect the powder from moisture, light, contamination, and physical damage while maintaining clear product and batch identification. Options may include:
Every package should carry the product name, CAS number, batch reference, quantity, and relevant handling information. Packaging must satisfy applicable carrier, export, import, and destination requirements.
AAS Raw Pharma does not offer disguised, mislabeled, or falsely declared shipments. Shipping documents and customs declarations must accurately identify the goods.
Samples may be available to qualified laboratories, institutions, and authorised buyers, subject to inventory, customer verification, destination law, and intended lawful use. Sample availability and any associated charges should be confirmed in writing.
For a sample or bulk quotation, provide:
Availability, minimum order quantity, pricing, production capacity, and lead time should be confirmed in a formal quotation. Avoid publishing “free samples” or guaranteed monthly capacity unless those terms are current and consistently fulfilled.
AAS Raw Pharma supports qualified customers seeking documented steroidal raw materials for lawful professional applications.
The listed purity is 99.3%, subject to the analytical results documented for the supplied batch.
The product is described using its correct chemical name, CAS number, molecular formula, and molecular weight, drawn from authoritative reference data rather than unverified supplier copy.
Customers may request the available COA, SDS, specification, and technical information for the current batch before purchase.
Direct commercial sourcing can support competitive quotations for approved development and bulk requirements. Final pricing depends on quantity, testing, packaging, stock, and destination.
Sample, development, and bulk requirements can be assessed according to stock, customer qualification, and applicable regulations.
Packaging is selected to protect the powder and preserve product and batch identification throughout lawful storage and transport.
The sales team can review logistics options for destinations where exportation, transport, importation, possession, and intended use are lawful.
Support is available for specifications, documentation, quotations, packaging, and shipment enquiries. Any discrepancy should be reported promptly with the relevant order and batch details.
Send AAS Raw Pharma complete and accurate purchasing information:
AAS Raw Pharma may request additional information before accepting an order. Submission of an enquiry does not guarantee availability, customs clearance, or approval.
International delivery may be considered where the shipment is lawful and accepted by an appropriate carrier. Possible providers may include DHL, FedEx, UPS, TNT, EMS, or a specialist freight service, depending on route, quantity, classification, and packaging.
The buyer is responsible for confirming import eligibility, customs classification, controlled-substance rules, veterinary or pharmaceutical licensing, carrier acceptance, duties and taxes, storage obligations, and local possession requirements.
Boldenone Cypionate is a controlled product in some countries and may require additional documentation and expense to import lawfully. AAS Raw Pharma does not guarantee customs clearance and does not support deceptive labels, false values, or inaccurate declarations.
Boldenone Cypionate Raw Powder is regulated differently across jurisdictions. Some countries classify boldenone esters as controlled anabolic substances; others regulate them as veterinary pharmaceutical ingredients, prescription-related materials, or prohibited sports substances.
Depending on destination and intended use, a purchaser may require controlled-substance registration, veterinary manufacturing authorisation, research approval, import or export permits, end-user declarations, secure storage, inventory reporting, or special disposal records.
The buyer should obtain independent legal and regulatory advice where necessary. Publication of this product page does not establish that the substance may be acquired, imported, or used in any particular location.
This page provides technical and commercial information about a raw chemical material. It does not recommend Boldenone Cypionate for bodybuilding, weight gain, strength, fat loss, endurance, athletic performance, veterinary self-treatment, or any personal application.
No dosage, treatment, injection, stacking, or cycle guidance is included. Such information is inappropriate for a bulk raw ingredient and could facilitate unsafe or unlawful administration. Boldenone Cypionate Raw Powder
AAS Raw Pharma does not claim that this raw material diagnoses, treats, cures, or prevents any disease. Any lawful veterinary treatment must be directed by a licensed veterinarian using an appropriately authorised finished product.
Boldenone Cypionate Raw Powder is the crystalline raw form of the cypionate ester of boldenone, supplied for qualified research, analytical, and legally authorised professional applications.
Bold Cyp is a common shorthand for Boldenone Cypionate. Formal documents should use the full chemical name and CAS number.
The CAS number is 106505-90-2.
The molecular formula is C27H38O3.
The molecular weight is approximately 410.59 g/mol.
Some raw-material catalogues show C26H38O3 and 398.58 g/mol, which do not match the CAS-assigned identity for Boldenone Cypionate. Authoritative reference sources report C27H38O3 and approximately 410.59 g/mol for CAS 106505-90-2.
The AAS Raw Pharma specification describes a white crystalline powder. Reference sources describe the material as a crystalline or off-white solid. Appearance alone cannot confirm identity or purity.
The stated purity is 99.3%, subject to the batch’s Certificate of Analysis.
Batch documentation may be available on request. Customers should confirm the exact COA, SDS, and specification supplied with their order.
AAS Raw Pharma lists it as a pharmaceutical raw-material grade, subject to an agreed specification. This does not mean the powder is a finished, sterile, or approved medicine.
Sterility must not be assumed. Unless a batch has been produced, tested, and released to a documented sterile specification, treat it as non-sterile raw material.
No. Raw powder is not a sterile injectable preparation and must not be injected or administered.
No. Raw material must not be administered directly. Veterinary treatment requires a licensed veterinarian and an authorised finished product.
No. Dosage, treatment, stacking, and cycle instructions are inappropriate for a bulk raw chemical.
No. They contain different ester groups and have different CAS numbers, formulas, and molecular weights.
No. Boldenone Cypionate and boldenone base are distinct substances with different identifiers.
Samples may be available to qualified customers, subject to inventory, intended use, verification, destination law, and commercial terms.
Bulk enquiries can be assessed according to stock, production capacity, documentation, quantity, customer qualification, and destination requirements.
Possible formats include sealed foil bags, protective containers, or approved bulk packaging, depending on quantity and transport needs.
Keep it sealed, protected from light, in a dry and secure location. Follow the exact conditions stated on the AAS Raw Pharma batch label and supporting documentation.
International delivery may be possible where exportation, transport, importation, possession, and intended use are lawful.
No. The buyer is responsible for permits, declarations, duties, taxes, and destination-country requirements.
Provide the quantity, destination, organisation details, intended lawful use, packaging preference, and required documentation. AAS Raw Pharma can then assess the enquiry. You can buy Boldenone Cypionate Raw Powder from us today
| Specification | Product details |
|---|---|
| Product name | Boldenone Cypionate Raw Powder |
| Chemical name | Boldenone cyclopentanepropionate |
| Alternative chemical description | 17-beta-hydroxyandrosta-1,4-dien-3-one cyclopentanepropionate |
| Common market name | Bold Cyp |
| CAS number | 106505-90-2 |
| Molecular formula | C27H38O3 |
| Molecular weight | Approximately 410.59 g/mol |
| Stated purity | 99.3%, subject to batch documentation |
| Appearance | White crystalline powder |
| Physical form | Crystalline solid |
| Listed grade | Pharmaceutical raw-material grade |
| Material category | Steroidal research and manufacturing raw material |
| Packaging | Sealed foil bag or approved bulk packaging |
| Documentation | Batch-specific documents available on request, where applicable |
| Intended users | Qualified laboratories, institutions, and authorised manufacturers |
| Direct administration | Not permitted; this is not a finished product |
